The Emergence of COVID-19 to Augment the Growth of the Vaccine Adjuvant Market

According to the Centers for Disease Control and Prevention (CDC), adjuvant is an ingredient used in vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better.

Growth of the vaccine adjuvant market is mainly driven by the outbreak of COVID-19 (the global pandemic). The use of an adjuvant is of importance in a pandemic where there is significant demand for a vaccine, since it may allow more doses to be produced from less ingredients and therefore enable manufacturing at scale.

For example, in May 2020, GSK confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates. Moreover, GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19. Adjuvant can reduce the amount of vaccine protein needed per dose, which allows more vaccine doses to be produced, contributing to the protection of more people. Furthermore, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections. This in turn is also expected to augment the growth of the vaccine adjuvant market.

According to credible sources, global vaccine adjuvants market size was valued at USD 0.70 billion in 2020 and is estimated to record a CAGR of 10.5% over 2021-2027.

Coherent Market Insights celebrating 5th anniversary and offering 2000 USD off on all reports. Let’s celebrate with us.

Buy Now and Get Instant Discount: https://www.coherentmarketinsights.com/promo/buynow/1731

Global Vaccine Adjuvants Market, by Product Type (Revenue, USD Billion, 2018-2027)
Pathogen Components
Adjuvant Emulsions
Particulate Adjuvants
Combination Adjuvants
Others

Global Vaccine Adjuvants Market, by Route of Administration (Revenue, USD Billion, 2018-2027)
Oral
Subcutaneous
Intranasal
Intramuscular
Intradermal
Others

Global Vaccine Adjuvants Market, by Application (Revenue, USD Billion, 2018-2027)
Research Applications
Commercial Applications

Global Vaccine Adjuvants Market, by Disease Type (Revenue, USD Billion, 2018-2027)
Infectious Diseases
Cancer
Others

The growth of the vaccine adjuvant market is also driven by the increasing prevalence of chronic diseases across the world. This in turn is expected to increase the demand for more improved and long lasting vaccination. According to the World Health Organization (WHO), chronic diseases, such as diabetes, cancer, and cardiovascular disease, are the leading causes of death and disability worldwide. According to the same source, in 2020, chronic disease prevalence were expected to increase by 57%. Moreover, with the increasing prevalence of infectious diseases, such as hepatitis, influenza, and HIV, demand for vaccine adjuvant is also increasing.

The augmenting factors for the growth of the vaccine adjuvants market include the increasing use of recombinant subunit and synthetic vaccines, expanding government recommendations for immunizations, technological innovations, and the unmet needs for vaccines against certain diseases. Thus, the introduction of innovative vaccine adjuvants may provide a better solution at a marginally lower cost. In March 2021, GlaxoSmithKline and Medicago announced the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study.

This in turn is also expected to accelerate the growth of the vaccine adjuvant market.

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/vaccine-adjuvant-market-1731

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle,
WA 98154, U.S.
Phone:
US: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

About Us:
Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. The company’s client base includes players from across various business verticals in over 47 countries globally. It takes pride in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and start-ups looking to establish a foothold in the market.

This release was published on openPR.